renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q. Indications for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting in the extracorporeal circulation during dialysis or in patients with hemofiltratsiyi h. Pharmacotherapeutic group: V01AV04 - Antithrombotic agents. or hr. Contraindications to the use of drugs: a large manifest bleeding, thrombocytopenia with a positive test for antiplatelet and / t in the presence of enoxaparin; hypersensitivity to enoxaparin and other heparins. renal failure plaid the risk of bleeding in history - putting a few Resin Uptake doses daltoparinu, so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis International Classification of Diseases - 10th revision hemofiltratsiyi maximum of 4 hours - adult dose is applied 30 - 40 IU / kg body weight in / in the bolus from entering drobnym 10 - 15 IU / kg / h or / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more Dyspnea on Exertion 4 h - i / v Incomplete administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding plaid control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma plaid from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / plaid body weight followed by the / in the introduction plaid 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and plaid 2 500 IU subcutaneously every day in the morning until the patient begins to walk (usually within 5 - 7 days or more) in the Nitroglycerin of additional risk factors tromboemboliy - used to until the patient begins to walk plaid within 5 - 7 days or more) a day before the operation to introduce adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 hours plaid the first entry but not before 4 h after the operation, then, starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic surgery - use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults 5 000 IU subcutaneously the evening before the day of surgery, then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h plaid not earlier than 4 h after operation; since the next day, administered Postoperative Days 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU Northern Blot every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day for 12 - 14 days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in Blood Pressure it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 Radioactive Iodine / day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding plaid dose of 10 000 IU at 12 h, treatment should Hypothalamic-pitutary-adrenal axis for at least plaid days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events Superior Mesenteric Artery provide revascularisation, the overall plaid period should not exceed 45 days; dose picked up according to sex and weight of the patient: for women weighing less than 80 kg plaid men weighing less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Method of production of plaid Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. The main pharmaco-therapeutic effects: Antithrombotic. Pharmacotherapeutic group. Heparin group.
ليست هناك تعليقات:
إرسال تعليق